Norditropin: payments to doctors
Payments that named Norditropin as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2M
- Providers
- 1,221
- Transactions
- 5,926
- Average per transaction
- $333
The per-transaction average — $333 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,221 providers the average total is $1,615, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $1,595,322 | 80.9% |
| Novo Nordisk Health Care AG | $351,631 | 17.8% |
| Novo Nordisk AS | $24,770 | 1.3% |